The US Food and Drug Administration approved modifications to the Risk Evaluation and Mitigation Strategy for mifepristone that permit retail pharmacists, as well as online pharmacists, to be certified to dispense the medication abortion. The change is expected to expand access, but many contend that a uniform federal program is needed to help those in states that ban or restrict use of the medication.
The US Food and Drug Administration announced in December 2021 that the REMS would be modified to remove the requirement that mifepristone be dispensed only in clinics, medical offices, and hospitals. It also added the requirement that pharmacies that dispense the drug be certified
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?